Conventional and emerging treatments and controversies in myasthenia gravis

References

• Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2(10):797–804.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. DOI:10.1038/s41572-019-0079-y
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Hagenacker T, Melzer N, et al. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242.
   Web of Science ®Google Scholar
• Koneczny I, Herbst R. Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019;8(7):671.
   PubMed Web of Science ®Google Scholar
• Unwin N. Nicotinic acetylcholine receptor and the structural basis of neuromuscular transmission: insights from Torpedo postsynaptic membranes. Q Rev Biophys. 2013;46(4):283–322.
   PubMed Web of Science ®Google Scholar
• Peeler CE, De Lott LB, Nagia L, et al. Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis. JAMA Neurol. 2015;72(10):1170–1174.
   PubMed Web of Science ®Google Scholar
• Cortés-Vicente E, Álvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020;94(11):e1171–1180. DOI:10.1212/WNL.0000000000008903
   PubMed Web of Science ®Google Scholar
• Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176–188.
   PubMed Web of Science ®Google Scholar
• Cron MA, Maillard S, Villegas J, et al. Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci. 2018;1412(1):137–145. DOI:10.1111/nyas.13519
   PubMed Web of Science ®Google Scholar
• Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol. 2014;9(Suppl 2):S137–142.
   PubMedGoogle Scholar
• Yasumizu Y, Ohkura N, Murata H, et al. Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma. Nat Commun. 2022;13(1):4230. DOI:10.1038/s41467-022-31951-8
   PubMed Web of Science ®Google Scholar
• Luo J, Lindstrom J. Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis. Ann N Y Acad Sci. 2018;1413:76–81.
   PubMed Web of Science ®Google Scholar
• Masuda T, Motomura M, Utsugisawa K, et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2012;83(9):935–940.
   PubMed Web of Science ®Google Scholar
• Fichtner ML, Jiang R, Bourke A, et al. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol. 2020;11:776.
   PubMed Web of Science ®Google Scholar
• Burden SJ, Huijbers MG, Remedio L. Fundamental molecules and mechanisms for forming and maintaining neuromuscular synapses. Int J Mol Sci. 2018;19(2):490.
   PubMed Web of Science ®Google Scholar
• Cartaud A, Strochlic L, Guerra M, et al. MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Bio. 2004;165(4):505–515. DOI:10.1083/jcb.200307164
   PubMed Web of Science ®Google Scholar
• Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology. 2005;64(3):536–538. DOI:10.1212/01.WNL.0000150587.71497.B6
   PubMed Web of Science ®Google Scholar
• Leite MI, Ströbel P, Jones M, et al. Fewer thymic changes in MuSK antibody positive than in MuSK antibody-negative MG. Ann Neurol. 2005;57(3):444–448. DOI:10.1002/ana.20386
   PubMed Web of Science ®Google Scholar
• Huijbers MG, Vink AF, Niks EH, et al. Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. J Neuroimmunol. 2016;291:82–88.
   PubMed Web of Science ®Google Scholar
• Koneczny I, Stevens JA, De Rosa A, et al. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. J Autoimmun. 2017;77:104–115. DOI:10.1016/j.jaut.2016.11.005
   PubMed Web of Science ®Google Scholar
• Vergoossen DLE, Plomp JJ, Gstöttner C, et al. Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proc Natl Acad Sci U S A. 2021;118(13):e2020635118. DOI:10.1073/pnas.2020635118
   PubMed Web of Science ®Google Scholar
• Bartoccioni E, Scuderi F, Minicuci GM, et al. Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology. 2006;67(3):505–507.
   PubMed Web of Science ®Google Scholar
• Li M, Han J, Zhang Y, et al. Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis. Eur J Neurol. 2019;26(10): 1296-e84. DOI:10.1111/ene.13979
   Web of Science ®Google Scholar
• Rivner MH, Quarles BM, Pan JX, et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study. Muscle Nerve. 2020;62(3):333–343. DOI:10.1002/mus.26985
   PubMed Web of Science ®Google Scholar
• Damato V, Spagni G, Monte G, et al. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(9):995–1000. DOI:10.1136/jnnp-2022-329284
   PubMed Web of Science ®Google Scholar
• Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–145.
   PubMed Web of Science ®Google Scholar
• Beck G, Yabumoto T, Baba K, et al. Double seronegative myasthenia gravis with anti-LRP4 antibodies presenting with dropped head and acute respiratory insufficiency. Intern Med. 2016;55(22):3361–3363. DOI:10.2169/internalmedicine.55.7030
   PubMed Web of Science ®Google Scholar
• Koneczny I, Rennspiess D, Marcuse F, et al. Characterization of the thymus in Lrp4 myasthenia gravis: four cases. Autoimmun Rev. 2019;18(1):50–55. DOI:10.1016/j.autrev.2018.07.011
   PubMed Web of Science ®Google Scholar
• Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445–451. DOI:10.1001/archneurol.2011.2393
   PubMedGoogle Scholar
• Shen C, Lu Y, Zhang B, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013;123(12):5190–5202. DOI:10.1172/JCI66039
   PubMed Web of Science ®Google Scholar
• Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin in myasthenia gravis patients. PLoS ONE. 2014;9(3):e91816. DOI:10.1371/journal.pone.0091816
   PubMed Web of Science ®Google Scholar
• Yan M, Liu Z, Fei E, et al. Induction of anti-agrin antibodies causes myasthenia gravis in mice. Neuroscience. 2018;373:113–121.
   PubMed Web of Science ®Google Scholar
• Devic P, Petiot P, Simonet T, et al. Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol. 2014;21(1):130–134. DOI:10.1111/ene.12270
   PubMed Web of Science ®Google Scholar
• Rodríguez Cruz PM, Al-Hajjar M, Huda S, et al. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 2015;72(6):642–649. DOI:10.1001/jamaneurol.2015.0203
   PubMed Web of Science ®Google Scholar
• Huda S, Waters P, Woodhall M, et al. IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e357. DOI:10.1212/NXI.0000000000000357
   PubMed Web of Science ®Google Scholar
• Mergenthaler P, Stetefeld HR, Dohmen C, et al. Seronegative myasthenic crisis: a multicenter analysis. J Neurol. 2022;269(7):3904–3911. DOI:10.1007/s00415-022-11023-z
   PubMed Web of Science ®Google Scholar
• Richards J, Howard JF Jr. Seronegative myasthenia gravis associated with malignant thymoma. Neuromuscular Disorders. 2017;27(5):417–418.
   PubMed Web of Science ®Google Scholar
• Katz NA, Barohn RJ. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis. Neuropharmacology. 2021;182:108303.
   PubMed Web of Science ®Google Scholar
• Evoli A, Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev. 2013;12(9):931–935.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology. 2011;77(20):1819–1826. DOI:10.1212/WNL.0b013e318237f660
   PubMed Web of Science ®Google Scholar
• Evoli A, Alboini PE, Damato V, et al. 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies. Neurology. 2016;86(11):1070–1071.
   PubMed Web of Science ®Google Scholar
• Haran M, Schattner A, Mate A, et al. Can a rare form of myasthenia gravis shed additional light on disease mechanisms? Clin Neurol Neurosur. 2013;115(5):562–566.
   PubMed Web of Science ®Google Scholar
• Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front Neurol. 2022;13:886625.
   PubMed Web of Science ®Google Scholar
• Farmakidis C, Pasnoor M, Dimachkie MM, et al. Treatment of myasthenia gravis. Neurol Clin. 2018;36(2):311–337.
   PubMed Web of Science ®Google Scholar
• Utsugisawa K, Nagane Y, Akaishi T, et al. Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve. 2017;55(6):794–801. DOI:10.1002/mus.25397
   PubMed Web of Science ®Google Scholar
• Lotan I, Hellmann MA, Wilf-Yarkoni A, et al. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. 2021;268(12):4573–4586.
   PubMed Web of Science ®Google Scholar
• Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687–693.
   PubMed Web of Science ®Google Scholar
• Ozawa Y, Uzawa A, Kanai T, et al. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis. J Neurol Sci. 2019;402:12–15.
   PubMed Web of Science ®Google Scholar
• Utsugisawa K, Suzuki S, Nagane Y, et al. Health-related quality-of-life and treatment targets in myasthenia gravis. Muscle Nerve. 2014;50(4):493–500. DOI:10.1002/mus.24213
   PubMed Web of Science ®Google Scholar
• Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020;410:116648.
   PubMed Web of Science ®Google Scholar
• Palace J, Newsom-Davis J, Lecky B, et al. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50(6):1778–1783. DOI:10.1212/WNL.50.6.1778
   PubMed Web of Science ®Google Scholar
• Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539–551.
   PubMed Web of Science ®Google Scholar
• Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol. 2005;53(3):146–150.
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu W, Li W, et al. Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord. 2017;10(9):315–325. DOI:10.1177/1756285617721092
   PubMed Web of Science ®Google Scholar
• Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.
   PubMed Web of Science ®Google Scholar
• Pasnoor M, He J, Herbelin L, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87(1):57–64. DOI:10.1212/WNL.0000000000002795
   PubMed Web of Science ®Google Scholar
• Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400–406. DOI:10.1212/01.wnl.0000312374.95186.cc
   PubMed Web of Science ®Google Scholar
• Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394–399. DOI:10.1212/01.wnl.0000312373.67493.7f
   PubMed Web of Science ®Google Scholar
• Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41(5):593–598.
   PubMed Web of Science ®Google Scholar
• Itani K, Nakamura M, Wate R, et al. Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis. Neuromuscular Disorders. 2021;31(6):512–518. DOI:10.1016/j.nmd.2021.02.010
   PubMed Web of Science ®Google Scholar
• Kassardjian CD, Widdifield J, Paterson JM, et al. Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol. 2020;27(4):702–708. DOI:10.1111/ene.14153
   PubMed Web of Science ®Google Scholar
• Verwijst J, Westerberg E, Punga AR. Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: a Swedish nationwide register study. Eur J Neurol. 2021;28(5):1706–1715.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13(5):847–58.e4. DOI:10.1016/j.cgh.2014.05.015
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang M, Xu L, et al. Cancer occurrence following azathioprine treatment in myasthenia gravis patients: a systematic review and meta-analysis. J Clin Neurosci. 2021;88:70–74.
   PubMed Web of Science ®Google Scholar
• De Feo LG, Schottlender J, Martelli NA, et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26(1):31–36.
   PubMed Web of Science ®Google Scholar
• Bryant A, Atkins H, Pringle CE, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol. 2016;73(6):652–658. DOI:10.1001/jamaneurol.2016.0113
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Meisel A. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. Expert Rev Neurother. 2022;22(4):313–318.
   PubMed Web of Science ®Google Scholar
• Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group. Ann Neurol. 1997;41(6):789–796. DOI:10.1002/ana.410410615
   PubMed Web of Science ®Google Scholar
• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–425. DOI:10.1212/WNL.0000000000002790
   PubMed Web of Science ®Google Scholar
• Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837–841.
   PubMed Web of Science ®Google Scholar
• Szczeklik W, Wawrzycka K, Włudarczyk A, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 2013;45(1):7–13. DOI:10.5603/AIT.2013.0002
   PubMedGoogle Scholar
• Alcantara M, Sarpong E, Barnett C, et al. Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol. 2021;28(2):639–646.
   PubMed Web of Science ®Google Scholar
• Evoli A, Meacci E. An update on thymectomy in myasthenia gravis. Expert Rev Neurother. 2019;19(9):823–833.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–522. DOI:10.1056/NEJMoa1602489
   PubMed Web of Science ®Google Scholar
• Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America. Neurology. 2000;55(1):16–23. DOI:10.1212/WNL.55.1.16
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18(3):259–268. DOI:10.1016/S1474-4422(18)30392-2
   PubMed Web of Science ®Google Scholar
• Lee I, Kuo HC, Aban IB, et al. Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. 2020;95(6):e755–766. DOI:10.1212/WNL.0000000000010031
   PubMed Web of Science ®Google Scholar
• Benatar M, Howard JF Jr, Barohn R, et al. Learning from the past: reflections on recently completed myasthenia gravis trials. Ann N Y Acad Sci. 2018;1412(1):5–13. DOI:10.1111/nyas.13501
   PubMed Web of Science ®Google Scholar
• Clifford KM, Hobson-Webb LD, Benatar M, et al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle Nerve. 2019;59(4):404–410. DOI:10.1002/mus.26404
   PubMed Web of Science ®Google Scholar
• Vander Heiden JA, Stathopoulos P, Zhou JQ, et al. Dysregulation of B cell repertoire formation in myasthenia gravis patients revealed through deep sequencing. J Immunol. 2017;198(4):1460–1473. DOI:10.4049/jimmunol.1601415
   PubMed Web of Science ®Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363. DOI:10.1016/S0140-6736(19)31817-3
   PubMed Web of Science ®Google Scholar
• Gomez AM, Vrolix K, Martínez-Martínez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol. 2011;186(4):2503–2513. DOI:10.4049/jimmunol.1002539
   PubMed Web of Science ®Google Scholar
• Kohler S, Märschenz S, Grittner U, et al. Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial. BMJ Open. 2019;9(1):e024523.
   PubMed Web of Science ®Google Scholar
• Oh S, Mao X, Manfredo-Vieira S, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023. Online ahead of print. DOI:10.1038/s41587-022-01637-z
   PubMed Web of Science ®Google Scholar
• Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscular Disorders. 2017;27(6):565–568.
   PubMed Web of Science ®Google Scholar
• Rowland SL, Leahy KF, Halverson R, et al. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J Immunol. 2010;185(8):4570–4581.
   PubMed Web of Science ®Google Scholar
• Ragheb S, Lisak R, Lewis R, et al. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol. 2008;65(10):1358–1362.
   PubMedGoogle Scholar
• Li X, Xiao BG, Xi JY, et al. Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol. 2008;126(2):180–188.
   PubMed Web of Science ®Google Scholar
• Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425–1434. DOI:10.1212/WNL.0000000000005323
   PubMed Web of Science ®Google Scholar
• Anderson D, Phan C, Johnston WS, et al. Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol. 2016;3(7):552–555.
   PubMed Web of Science ®Google Scholar
• Robeson KR, Kumar A, Keung B, et al. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis. JAMA Neurol. 2017;74(1):60–66. DOI:10.1001/jamaneurol.2016.4190
   PubMed Web of Science ®Google Scholar
• Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193. DOI:10.1212/WNL.0b013e3182407982
   PubMed Web of Science ®Google Scholar
• Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology. 2017;89(10):1069–1077. DOI:10.1212/WNL.0000000000004341
   PubMed Web of Science ®Google Scholar
• Stathopoulos P, Kumar A, Nowak RJ, et al. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight. 2017;2(17):e94263. DOI:10.1172/jci.insight.94263
   PubMed Web of Science ®Google Scholar
• Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of Myasthenia Gravis: 2020 update. Neurology. 2021;96(3):114–122. DOI:10.1212/WNL.0000000000011124
   PubMed Web of Science ®Google Scholar
• Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2021;98(4):e376–389. DOI:10.1212/WNL.0000000000013121
   PubMed Web of Science ®Google Scholar
• Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105–1112. DOI:10.1001/jamaneurol.2022.2887
   PubMed Web of Science ®Google Scholar
• Dos Santos A, Noury JB, Genestet S, et al. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol. 2020;27(11):2277–2285. DOI:10.1111/ene.14391
   PubMed Web of Science ®Google Scholar
• Caballero-Ávila M, Álvarez-Velasco R, Moga E, et al. Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia. Neuromuscular Disorders. 2022;32(8):664–671. DOI:10.1016/j.nmd.2022.06.006
   PubMed Web of Science ®Google Scholar
• Howard JF. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113–128.
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Herbelin L, Nations SP, et al. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487–1489.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–986. DOI:10.1016/S1474-4422(17)30369-1
   PubMed Web of Science ®Google Scholar
• Nowak RJ, Muppidi S, Beydoun SR, et al. Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study. Front Neurol. 2020;11:556104.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology. 2021;96(4):e610–618. DOI:10.1212/WNL.0000000000011207
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Karam C, Yountz M, et al. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Ann Clin Transl Neurol. 2021;8(7):1398–1407. DOI:10.1002/acn3.51376
   PubMed Web of Science ®Google Scholar
• Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14–24. DOI:10.1002/mus.26447
   PubMed Web of Science ®Google Scholar
• Katyal N, Narula N, Govindarajan R. Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis. J Neuromuscul Dis. 2021;8(2):287–294.
   PubMedGoogle Scholar
• Oyama M, Okada K, Masuda M, et al. Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord. 2020;13:1756286420904207.
   Web of Science ®Google Scholar
• Vu T, Harvey B, Suresh N, et al. Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: a case report. Case Rep Neurol. 2021;13(1):65–71.
   PubMed Web of Science ®Google Scholar
• Nelke C, Schroeter CB, Stascheit F, et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(5):548–554. DOI:10.1136/jnnp-2021-328665
   PubMed Web of Science ®Google Scholar
• Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4):e0195909. DOI:10.1371/journal.pone.0195909
   PubMed Web of Science ®Google Scholar
• Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5). DOI:10.1056/EVIDoa2100066
   Google Scholar
• Dalakas MC, Alexopoulos H, Spaeth P. Complement in autoimmune neurological disorders and emerging complement-targeted therapeutics. Nature Rev Neurol. 2020;16:601–617. DOI:10.1038/s41582-020-0400-0
   PubMed Web of Science ®Google Scholar
• Lewis LA, Ram S. Complement interactions with the pathogenic Neisseriae: clinical features, deficiency states, and evasion mechanisms. FEBS Lett. 2020;594(16):2670–2694.
   PubMed Web of Science ®Google Scholar
• Socié G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297–310. DOI:10.1111/bjh.15790
   PubMed Web of Science ®Google Scholar
• Pyzik M, Sand KMK, Hubbard JJ, et al. The neonatal Fc receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540.
   PubMed Web of Science ®Google Scholar
• Keller CW, Pawlitzki M, Wiendl H, et al. Fc-Receptor targeted therapies for the treatment of myasthenia gravis. Int J Mol Sci. 2021;22(11):5755.
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–536. DOI:10.1016/S1474-4422(21)00159-9
   PubMed Web of Science ®Google Scholar
• Peter HH, Ochs HD, Cunningham-Rundles C, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020;146(3):479–491.e5. DOI:10.1016/j.jaci.2020.07.016
   PubMed Web of Science ®Google Scholar
• Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020;77(8):974–981.
   PubMed Web of Science ®Google Scholar
• Benatar M, Cutter G, Kaminski HJ. The best and worst of times in therapy development for myasthenia gravis. Muscle Nerve. 2023;67(1):12–16.
   PubMedGoogle Scholar
• Tannemaat MR, Verschuuren JJGM. Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids. Neuromuscular Disorders. 2020;30(2):111–119.
   PubMed Web of Science ®Google Scholar
• Yildiz Celik S, Durmus H, Yilmaz V, et al. Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome. Acta Neurol Belg. 2020;120(1):133–140. DOI:10.1007/s13760-019-01252-x
   PubMed Web of Science ®Google Scholar
• Hellmann MA, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. J Neurol Sci. 2013;325(1–2):1–5.
   PubMed Web of Science ®Google Scholar
• Cortés-Vicente E, Álvarez-Velasco R, Pla-Junca F, et al. Drug-refractory myasthenia gravis: clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol. 2022;9(2):122–131. DOI:10.1002/acn3.51492
   PubMed Web of Science ®Google Scholar
• Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255–260.
   PubMedGoogle Scholar